Analysts at HC Wainwright cut their FY2024 earnings estimates for shares of Mawson Infrastructure Group in a note issued to investors on Tuesday, November 26th. HC Wainwright analyst K. Dede now ...

Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for Oruka Therapeutics in a research report issued ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. downgraded their outlook for Mainz Biomed N.V. (NasdaqCM:MYNZ) ...

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of SoundHound AI ...

To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

H.C. Wainwright analyst Matthew Caufield initiated coverage of Immunic (IMUX) with a Buy rating and $10 price target The firm likes the company’s “comprehensive” neuroprotective and anti ...

H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring ...

On Tuesday, H.C. Wainwright maintained a Neutral rating for Mawson Infrastructure Group Inc. (NASDAQ: MIGI), following the company's recent production report. Mawson Infrastructure, transitioning from ...

On Tuesday, H.C. Wainwright maintained a Neutral rating for Mawson Infrastructure Group Inc. (NASDAQ: MIGI), following the company's recent production report. Mawson Infrastructure, transitioning ...